切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2016, Vol. 05 ›› Issue (01) : 10 -13. doi: 10.3877/cma.j.issn.2095-3216.2016.01.003

所属专题: 文献

专家论坛

慢性肾脏病患者高尿酸血症的管理
李英1()   
  1. 1. 050081 石家庄,河北医科大学第三医院肾内科、河北省肾脏病研究中心
  • 收稿日期:2015-12-16 出版日期:2016-02-28
  • 通信作者: 李英

Management of hyperuricemia in patients with chronic kidney disease

Ying Li1,()   

  1. 1. Department of Nephropathy, Hebei Medical University Affiliated Third Hospital, Hebei Province Kidney Disease Research Center, Shijiazhuang 050081, Hebei, China
  • Received:2015-12-16 Published:2016-02-28
  • Corresponding author: Ying Li
  • About author:
    Corresponding author: Li Ying, Email:
引用本文:

李英. 慢性肾脏病患者高尿酸血症的管理[J/OL]. 中华肾病研究电子杂志, 2016, 05(01): 10-13.

Ying Li. Management of hyperuricemia in patients with chronic kidney disease[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2016, 05(01): 10-13.

生理情况下,人体每日尿酸的产生和排泄基本上保持动态平衡。若血清尿酸水平男>420 μmol/L,女>360 μmol/L则称为高尿酸血症。随着居民生活方式、饮食结构的改变以及人口老龄化,高尿酸血症的发病率呈逐年上升趋势。越来越多的研究表明高尿酸血症与慢性肾脏病(CKD)的关系密切。尿酸是嘌呤核苷酸代谢中不易溶解的循环终产物,CKD患者肾小球滤过率降低时,高尿酸血症发生的风险增加,而长期的高尿酸血症会导致肾功能的进行性恶化,增加患者心血管疾病的发生风险及死亡率。因此做好CKD患者高尿酸血症的管理具有重要的临床意义。关于高尿酸血症诊断和治疗有多项专家共识和指南,即改善生活方式是治疗的基础,早期干预和综合管理是治疗的核心。

Under the physiological condition, human daily production and excretion of uric acid are maintained basically at a dynamic balance.When serum uric acid level is higher than 420 μmol/L in men or 360 μmol/L in women, there is hyperuricemia. With the change of life style, diet structure, and increase of aging population, the incidence of hyperuricemia is increasing year by year. Recently more and more researches have indicated that hyperuricemia is closely related to chronic kidney disease (CKD). Uric acid is the poorly soluble circulating end product of the purine nucleotide metabolism. A reduction in the glomerular filtration rate (GFR) contributes to hyperuricemia. Long- term hyperuricemia can lead to progressive deterioration of renal function, increasing the risk of cardiovascular disease in patients with increased mortality. It is important to investigate the management for CKD patients with hyperuricemia. There are expert consensus and guidelines for diagnosis and treatment of the hyperuricemia. The basis of treatment is improving the life style, and the core of treatment are early intervention and comprehensive management.

1
Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross- sectional survey [J]. Lancet, 2012, 379(9818): 815-822.
2
Hsu CY, Iribarren C, McCulloch CE, et al. Risk factors for end- stage renal disease: 25- year follow- up [J]. Arch Intern Med, 2009, 169(4): 342-350.
3
Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease [J]. J Am Soc Nephrol, 2008, 19(12): 2407-2413.
4
Kim WJ, Kim SS, Bae MJ, et al. High- normal serum uric acid predicts the development of chronic kidney disease in patients with type 2 diabetes mellitus and preserved kidney function [J]. J Diabetes Complications, 2014, 28(2): 130-134.
5
Liu YL, Pan Y, Wang X, et al. Betaine reduces serum uric acid levels and improves kidney function in hyperuricemic mice [J]. Planta Med, 2014, 80(1): 39-47.
6
Chuengsamarn S, Rattanamongkolgul S, Jirawatnotai S. Association between serum uric acid level and microalbuminuria to chronic vascular complications in Thai patients with type 2 diabetes [J]. J Diabetes Complications, 2014, 28(2): 124-129.
7
Prasad SO, Qing YX. Associations between hyperuricemia and chronic kidney disease: a review [J]. Nephrourol Mon, 2015, 7(3): e27233.
8
Wang S, Chen R, Liu Q, et al. Prevalence, awareness and treatment of chronic kidney disease among middle- aged and elderly: the China health and retirement longitudinal study [J]. Nephrology (Carlton), 2015, 20(7): 474-484.
9
Yang B, Mo Z, Wu C, et al. A genome- wide association study identifies common variants influencing serum uric acid concentrations in a Chinese population [J]. BMC Med Genomics, 2014, 7: 10.
10
Mallamaci F, Testa A, Leonardis D, et al. A genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: a family- based study [J]. Am J Kidney Dis, 2015, 65(2): 294-302.
11
Kumral E, Karaman B, Orman M, et al. Association of uric acid and carotid artery disease in patients with ischemic stroke [J]. Acta Neurol Scand, 2014, 130(1): 11-17.
12
唐湘玲,陈梦颖,张卫茹. 慢性肾脏病患者血清内脏脂肪素水平升高及其与颈动脉粥样硬化的关系[J].中南大学学报(医学版), 2013,38(6): 554-559.
13
Bao X, Wang Q, Chen G, et al. Serum concentration of uric acid associated with prehypertension among Chinese population [J]. Angiology, 2014, 65(9): 800-805.
14
Liu YL, Pan Y, Wang X, et al. Betaine reduces serum uric acid levels and improves kidney function in hyperuricemic mice [J]. Planta Med, 2014, 80(1): 39-47.
15
Cai G, Zheng Y, Sun X, et al. Prevalence, awareness, treatment, and control of hypertension in elderly adults with chronic kidney disease: results from the survey of prevalence, awareness, and treatment rates in chronic kidney disease patients with hypertension in China [J]. J Am Geriatr Soc, 2013, 61(12): 2160-2167.
16
中华医学会内分泌学分会. 高尿酸血症和痛风治疗的中国专家共识[J]. 中华内分泌代谢杂志,2013,29(11): 913-920.
17
Hamburger M, Baraf HS, Adamson TR, et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia [J]. Phys Sportsmed, 2011, 39(4): 98-123.
18
Soltani Z, Rasheed K, Kapusta DR, et al. Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal [J]? Curr Hypertens Rep, 2013, 15(3): 175-181.
19
Qiu L, Cheng XQ, Wu J, et al. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces [J]. BMC Public Health, 2013, 13: 664.
20
Xue C, Ye XD, Li W, et al. Prevalence of chronic kidney disease in Jing adults in China: a village- based study [J]. Clin Nephrol, 2013, 79(1): 50-56.
21
Goicoechea M, Garcia DVS, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: long- term follow- up of a randomized clinical trial [J]. Am J Kidney Dis, 2015, 65(4): 543-549.
22
Bellomo G. The relationship between uric acid, allopurinol, cardiovascular events, and kidney disease progression: a step forward [J]. Am J Kidney Dis, 2015, 65(4): 525-527.
23
Park DJ, Kang JH, Lee JW, et al. Cost- effectiveness analysis of HLA- B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea [J]. Arthritis Care Res (Hoboken), 2015, 67(2): 280-287.
24
Sakai Y, Otsuka T, Ohno D, et al. Febuxostat for treating allopurinol- resistant hyperuricemia in patients with chronic kidney disease [J]. Ren Fail, 2014, 36(2): 225-231.
25
Kobayashi S, Ogura M, Hosoya T. Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease [J]. J Clin Pharm Ther, 2013, 38(3): 258-261.
26
Ohno I. The cutting- edge of medicine; role of hyperuricemia in cardiorenal syndrome [J]. Nihon Naika Gakkai Zasshi, 2013, 102(6): 1484-1491.
27
Yood RA, Ottery FD, Irish W, et al. Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo- controlled, phase 3 clinical trials [J]. BMC Res Notes, 2014, 7: 54.
28
Bleyer AJ, Wright D, Alcorn H. Pharmacokinetics and pharmacodynamics of pegloticase in patients with end- stage renal failure receiving hemodialysis [J]. Clin Nephrol, 2015, 83(5): 286-292.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 周易, 张红梅, 尹立雪, 杨浩, 付培. 四川省超声医学质量控制指标动态变化趋势分析[J/OL]. 中华医学超声杂志(电子版), 2024, 21(07): 664-670.
[3] 王晓娜, 张宁, 宋伟, 杨明, 李丽, 薛红元. 河北省超声医学质量管理与控制现状分析[J/OL]. 中华医学超声杂志(电子版), 2024, 21(07): 675-680.
[4] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[5] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[6] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[7] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[8] 石海波, 赵旭东, 王聪, 曲巍. 气肿性肾盂肾炎、气肿性膀胱炎并脓毒性休克一例报道并文献复习[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 644-647.
[9] 林逸, 钟文龙, 李锴文, 何旺, 林天歆. 广东省医学会泌尿外科疑难病例多学科会诊(第15期)——转移性膀胱癌的综合治疗[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 648-652.
[10] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[11] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[12] 陈秀梅, 陈思涓, 郑小静. 护理联盟体构建及实践的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 703-708.
[13] 李茂军, 唐彬秩, 吴青, 阳倩, 梁小明, 邹福兰, 黄蓉, 陈昌辉. 新生儿呼吸窘迫综合征的管理:多国指南/共识及RDS-NExT workshop 共识陈述简介和评价[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 607-617.
[14] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[15] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
阅读次数
全文


摘要